Os níveis de fenóis solúveis totais e a atividade das enzimas oxidativas polifenoloxidases e peroxidases foram estudados em tecidos foliares sadios dos clones de cacaueiro (Theobroma cacao) SCA 6, TSH 1188, TSH 565, TSH 516, EET 397, EET 62, TSA 641, SIAL 505, RIM 106, RIM 52, SIC 24 e UF 613, com o objetivo de estudar possível(is) mecanismo(s) de resistência de cacaueiro a Crinipellis perniciosa. Os níveis de fenóis solúveis totais foram mais elevados em clones de cacaueiro com resistência a C. perniciosa, e podem estar contribuindo na resposta de defesa contra o patógeno. A atividade de polifenoloxidases foi menor nos clones resistentes do que nos clones suscetíveis. A atividade de peroxidases em folhas maduras foi menor nos clones resistentes, mas em folhas jovens não foi possível estabelecer uma relação da atividade de peroxidase com os clones resistentes. Os níveis de fenóis e a atividade das enzimas oxidativas correlacionaram-se de forma inversa na maioria dos clones estudados, o que pode indicar uma inibição das enzimas peroxidases e polifenoloxidases pelos compostos fenólicos.

The levels of total soluble phenols and the activity of the oxidative enzymes polyphenol oxidases and peroxidases were studied in healthy leaf tissue of cocoa (Theobroma cacao) clones SCA 6, TSH 1188, TSH 565, TSH 516, EET 397, EET 62, TSA 641, SIAL 505, RIM 106, RIM 52, SIC 24 and UF 613, for the purpose of detecting the possible resistance mechanism(s) to Crinipellis perniciosa. The total soluble phenol content of T. cacao clones with resistance to C. perniciosa was generally higher than in the susceptible clones, which may contribute to defense against the pathogen. The activity of polyphenol oxidases was lower in the resistant clones compared to the susceptible ones. The activity of peroxidases in mature leaves was lower in resistant clones, but when considering young leaves it was not possible to establish a clear relation between the activity of this enzyme with resistance. The levels of soluble phenols and the activity of oxidative enzymes studied were inversely correlated in the majority of the studied clones, suggesting a possible inhibition of the oxidative enzymes by phenols.

This study aimed at evaluating the efficacy and safety of meropenem as first choice treatment for nosocomial pneumonia (NP) in intensive care units (ICU) in Hospital das Clínicas (HC) - University of São Paulo; a hospital with high incidence of antimicrobial resistance. Prospective, open, and non-comparative trial with meropenem were done in patients with ventilator-associated or aspiration NP in 2 ICUs at HC - University of São Paulo. Etiologic investigation was done through bronchoalveolar lavage and blood cultures prior to study entry. Twenty-five (25) critically ill patients with NP were enrolled (mean age 40 years). Ventilator-acquired pneumonia was responsible for 76% of cases and aspiration NP for 24%. Specific etiologic agents were identified and considered to be clinically and temporally responsible for NP in 11 (44%) patients. A. baumanii was responsible for 6 cases (55%), P. aeruginosa for 3 (27%), and S. aureus for 2 (18%). At completion of treatment, 19 patients (76%) showed either cure (48%) or improvement (28%) after use of meropenem therapy. Mortality was 12% at the end of therapy (8% after excluding 1 non-evaluable patient). After 4 to 6 weeks of follow-up, 12 (48%) patients had improved or been totally cured, and overall mortality was 24%. Clinical complications were observed in 11 patients (44%), with none of them definitely related to the study drug. Meropenem as monotherapy was effective and well-tolerated in most NP patients in our ICU. The low mortality rate in this study might have been due to first choice use of this drug. Controlled, drug comparative clinical trials are needed to support this preliminary observation.

Na última década, a Legionella sp tem surgido como uma causa importante de pneumonia, tanto hospitalar quanto comunitária. Depois da detecção de um surto hospitalar numa unidade de Transplantados Renais, amostras de soro estocado em laboratório foram testadas para anticorpos anti-Legionella pneumophila sorogrupo 1. Cinco casos de Doença dos Legionários foram revistos. Os aspectos clínicos e laboratoriais eram semelhantes aos esperados em pneumonias de outras etiologias, mas houve a presença de icterícia importante em 2 casos. Dentre os 5 casos apresentados neste estudo, 2 foram de aquisição nosocomial e 3 foram comunitários. Já foi descrito um surto de infecção hospitalar por Legionella pneumophila sorogrupo 1 no nosso meio³. Em 1989 foi descrito o primeiro caso de pneumonia por Legionella pneumophila no nosso meio². No entanto pouca importância é dada a este agente etiológico quando se considera o tratamento empírico das pneumonias comunitárias. Este estudo sugere que a real incidência de pneumonia causada por Legionella sp está sendo subestimada e os autores enfatizam a importância de considerar a Doença dos Legionários no tratamento empírico de pneumonias adquiridas na comunidade

Legionella sp has been emerging over the last decade as an important cause of pneumonia both hospital and community-acquired. Following an outbreak in a Renal - Transplant Unit stocked serum was tested for antibodies against Legionella pneumophila serogroup 1, and 5 cases of Legionnaires' Disease were reviewed. Two of the cases were nosocomial and three cases were community - acquired. Clinical and laboratorial aspects were similar to those expected for other causes of pneumonia, however jaundice was encountered in two cases. This study suggests that the real incidence of pneumonia caused by Legionella sp is being underestimated and the authors emphasize the importance of considering Legionnaires' Disease when empirically treating community - acquired pneumonia

O objetivo deste estudo consistiu em avaliar pentamidina inalatória para o tratamento de pneumonia leve a moderada, causada por Pneumocystis carinii. Oito adultos com a síndrome da imunodeficiência humana e pneumocistose (4 apresentando o primeiro episódio e 4 na vigência de pneumocistose de repetição) receberam inalações diárias de isetionato de pentamidina por 21 dias. Seis pacientes foram tratados com doses de 300 mg de pentamidina e os 2 restantes receberam 600 mg diariamente. No grupo de 300 mg, 2 indivíduos desenvolveram neutropenia leve e transitória. Porém, ambos os pacientes recebendo 600 mg de pentamidina aerosol apresentaram leucopenia. Um deles teve toxicidade importante (intolerância global de 12,5%), que levou a suspensão da droga e impediu a avaliação da sua eficácia. Entre os 7 pacientes que puderam ser avaliados, 6 (86%) completaram o tratamento com sucesso. Um paciente que recebeu 300 mg de pentamidina diariamente teve uma recorrência precoce. Em conclusão, a pentamidina inalatória representa uma modalidade terapêutica eficaz contra a pneumonia por Pneumocystis carinii. E menos tóxica do que as drogas usadas convencionalmente e também pode ser administrada ambulatorialmente.

The goal of this study was to evaluate inhaled pentamidine for the treatment of patients with mild and moderate Pneumocystis carinii pneumonitis. Eight adults with AIDS and pneumocystis pneumonia (4 with a first episode and 4 with a repeat pneumocystosis) received daily inhalations of aerosol pentamidine isethionate for 21 days. Six patients were treated with doses of 300 mg of pentamidine and the remaining 2 received 600 mg every day. In the 300 mg treatment group, 2 individuals showed discrete and transient neutropenia. However, both subjects that received 600 mg of aerosol pentamidine daily developed leukopenia. One of them had major toxicity (overall severe intolerance of 12.5%) that required drug discontinuation and did not allow any analysis of the treatment efficacy. Of the 7 evaluable patients, 6 (88%) completed the treatment successfuly. One subject of the 300 mg regimen experienced an early recurrence. In conclusion, inhaled pentamidine is an effective treatment for mild and moderate cases of P. carinii pneumonia. It is less toxic than standard anti-pneumocystis therapy and is suitable for outpatient use.